Picture of medmix AG logo

MEDX — medmix AG News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Switzerland's Medmix FY revenue falls 4.8% on weakness in beauty business

Overview

Switzerland delivery device maker's FY revenue declined 4.8% organically

Adjusted EBITDA margin improved to 20%, driven by higher Dental volumes and efficiency gains

Net income rose to CHF 7.0 mln from a loss in the previous year

Outlook

Medmix expects 2026 organic revenue growth to be flat to low single digits

Company forecasts 2026 adjusted EBITDA margin around 20%

Medmix increases mid-term adjusted EBITDA margin guidance to above 21%

Result Drivers

BEAUTY DEMAND - Revenue in the Beauty segment fell 12.9% due to weak end markets and project delays

DUAL SOURCING IMPACT - Drug Delivery revenue dropped 19.6% due to customer dual sourcing and non-repeat project milestones

EFFICIENCY GAINS - Improved margins attributed to cost savings and efficiency gains from Growth & Efficiency program

Key Details

MetricBeat/MissActualConsensus Estimate
FY RevenueMissCHF 448 mlnCHF 453.65 mln (2 Analysts)
FY Adjusted EBITDACHF 89.70 mln
FY Adjusted EBITDA Margin20.00%
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell" The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy" Wall Street's median 12-month price target for medmix AG is CHF18.00, about 58.2% above its February 25 closing price of CHF11.38 The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 16 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on medmix AG

See all news